Role of Glutamate Decarboxylase-like Protein 1 (GADL1) in Taurine Biosynthesis*

Pingyang Liu†, Xiaomei Ge§, Haizhen Ding‡, Honglin Jiang§, Bruce M. Christensen‡, and Jianyong Li*†§

From the Departments of Biochemistry and Animal and Poultry Sciences, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061 and the Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706

Background: The biochemical activities and tissue distribution of GADL1 have remained unknown.

Results: GADL1 is expressed in muscles and kidneys; it catalyzes decarboxylation of aspartate, cysteine sulfinic acid, and cysteic acid to produce β-alanine, hypotaurine, and taurine.

Conclusion: GADL1 has aspartate 1-decarboxylase and cysteine sulfinic acid decarboxylase activities.

Significance: GADL1 could potentially participate in mammalian taurine biosynthesis.

This manuscript concerns the tissue-specific transcription of mouse and cattle glutamate decarboxylase-like protein 1 (GADL1) and the biochemical activities of human GADL1 recombinant protein. Bioinformatic analysis suggested that GADL1 appears late in evolution, only being found in reptiles, birds, and mammals. RT-PCR determined that GADL1 mRNA is transcribed at high levels in mouse and cattle skeletal muscles and also in mouse kidneys. Substrate screening determined that GADL1, unlike its name implies, has no detectable GAD activity, but it is able to efficiently catalyze decarboxylation of aspartate, cysteine sulfinic acid, and cysteic acid to β-alanine, hypotaurine, and taurine, respectively. Western blot analysis verified the presence of GADL1 in mouse muscles, kidneys, C2C12 myoblasts, and C2C12 myotubes. Incubation of the supernatant of fresh muscle or kidney extracts with cysteine sulfinic acid resulted in the detection of hypotaurine or taurine in the reaction mixtures, suggesting the possible involvement of GADL1 in taurine biosynthesis. However, when the tissue samples were incubated with aspartate, no β-alanine production was observed. We proposed several possibilities that might explain the inactivation of ADC activity of GADL1 in tissue protein extracts. Although β-alanine-producing activity was not detected in the supernatant of tissue protein extracts, its potential role in β-alanine synthesis cannot be excluded. There are several inhibitors of the ADC activity of GADL1 identified. The discovery of GADL1 biochemical activities, in conjunction with its expression and activities in muscles and kidneys, provides some tangible insight toward establishing its physiological function(s).

This work was supported, in whole or in part, by National Institutes of Health Grant AI19769.

† This article contains supplemental Table S1 and Figs. S1–S7.
§ To whom correspondence should be addressed: Dept. of Biochemistry, Engel Hall 204, Virginia Polytechnic Inst. and State University, Blacksburg, VA 24061. Tel.: 540-231-5779; Fax: 540-231-9070; E-mail: lij@vt.edu.

* The abbreviations used are: GABA, γ-aminobutyric acid; GADL1, glutamate decarboxylase-like protein 1; GAD, glutamate decarboxylase; PLP, pyridoxal-5'-phosphate; ADC, aspartate 1-decarboxylase; CSADC, cysteine sulfinic acid decarboxylase; OPT, α-phthalaldehyde.

© 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

** This work was supported, in whole or in part, by National Institutes of Health Grant AI19769.
established that skeletal muscles contain high concentrations of carnosine whose synthesis occurs primarily in muscles (based on the presence and activity of muscle carnosine synthase) (11, 12). β-Alanine is indispensable for carnosine synthesis, and oral consumption of β-alanine could significantly improve the muscular carnosine concentrations, although a considerable portion of the β-alanine would be digested before reaching to muscles (13, 14). This suggests that in situ synthesis of β-alanine would be advantageous for carnosine synthesis. Muscles have high levels of taurine concentration, whereas the muscular taurine is mostly synthesized in livers and transported to muscles via the taurine transporter (15). It has generally been considered that taurine and β-alanine are not synthesized in muscles, but the similarity of GADL1 to mammalian CSADC and insect ADC, together with its high expression levels in muscles, provides a basis to speculate that GADL1 could use cysteine sulfinic acid or/and aspartate as a substrate, therefore likely involving in taurine or/and β-alanine biosynthesis.

In this study, we expressed recombinant human GADL1 and examined its activity to different amino acids, which resulted in the detection of decarboxylation activity of both aspartate and cysteine sulfinic acid. GADL1 does not work on glutamate as its name suggests. Subsequently, we analyzed the transcript and protein levels of GADL1 in mice and cattle, determining that its mRNA and protein were present primarily in skeletal muscles of both species. The transcription and expression of GADL1 in muscles and the ability of its recombinant protein to produce β-alanine and hypotaurine through decarboxylation of aspartate and cysteine sulfinic acid, respectively, suggest that the decarboxylation of aspartate and cysteine sulfinic acid could be a route of β-alanine and hypotaurine synthesis in skeletal muscles. Then, we were able to detect the hypotaurine-producing activities in the supernatant of protein extracts from muscle and kidney tissues. A number of endogenous compounds were shown to inhibit the ADC activity of GADL1.

EXPERIMENTAL PROCEDURES

Chemicals—All of the chemicals used in this report were from Sigma-Aldrich unless specified otherwise.

Tissue Collection—Mouse tissues were collected from two male mice –8 weeks old. Bovine tissues were collected from two Holstein bulls –5 years old at slaughter. The tissue samples were immediately frozen in liquid nitrogen and stored at −80 °C until RNA isolation.

Cell Culture—C2C12 myoblasts were cultured in growth medium (DMEM with 10% FBS and 1% antibiotic antimycotic). C2C12 myotubes were cultured in differentiation medium (DMEM with 2% horse serum and 1% antibiotic antimycotic) for 72 h before experiments.

Expression and Purification of GADL1—To express HuGADL1, a forward primer (5′-AAACATATGTCTTCCAGTAAAGAATGCT-3′) containing a NdeI site (underlined nucleotides) and a reverse primer (5′-AAAGAATTCACATGGTCTTTACCCAGTAAGTCTA-3′) containing an EcoRI site (underlined nucleotides) were designed and used to amplify HuGADL1 from human liver cDNA. The amplified HuGADL1 cDNA was cloned into an Impact-CN plasmid (New England Biolabs) for expression of its recombinant protein. The frame of the HuGADL1 was verified by DNA sequencing. Escherichia coli BL 21 cells with the expression vector were induced at 0.15 mM of isopropyl β-D-1-thiogalactopyranoside when optical density reached 1.0 and grew for 24 h at 15 °C before breaking the cells in a suggested lysis buffer. The recombinant enzyme was obtained from E. coli BL 21 cells. The concentrated protein sample was further purified by ion exchange and gel filtration chromatographies (Mono-Q column and Sepharose 12; GE Healthcare) with 20 mM phosphate buffer (pH 7.0). Protein concentrations were determined by a Bio-Rad protein assay using bovine serum albumin as a standard. The spectrum of HuGADL1 was recorded using a Hitachi U2800 UV-visible spectrophotometer.
Role of GADL1 in Taurine Biosynthesis

Substrate Screening—The purified recombinant HuGADL1 was used for substrate screening. Each reaction mixture of 200 μl containing 10 μg of purified recombinant protein and 40 μl of 50 mM of a substrate (aspartate, cysteine sulfinic acid, cysteic acid, or glutamate) was prepared in 150 mM phosphate buffer (pH 7.0) with 0.40 μM of PLP. The reaction mixtures were incubated for 10 min at 25 °C and stopped by adding two volumes of 100% ethanol. The specific activities and standard deviations were calculated based on the averages of triplicates. The mixtures were derivatized by two volumes of 100% ethanol. The specific activities and standard deviations were calculated based on standard curves of homogenization was the same to the previous lysis buffer (9). Determination of the products was based on the detection of OPT derivatives by reverse phase liquid chromatography with electrochemical detection. The mobile phase consisted of 50 mM of phosphate buffer (pH 3.5) containing 25% acetonitrile at a flow rate of 0.5 ml per min. The oxidation potential of the working electrode was set to +0.75 V. The activities of HuGADL1 toward the substrates were calculated based on standard curves generated with authentic standards at the identical conditions.

After the substrate specificity of GADL1 was determined, protein extracts from either mouse muscles or mouse kidneys were obtained and assayed for decarboxylation of aspartate and cysteine sulfinic acid. The extracts were obtained from raw tissues by homogenization in 100 mM HEPES buffer (pH 7.5). 1 mM of MgCl₂, 10 μM of PLP, 2 mM of β-mercaptoethanol, and 20 μM of phenylmethanesulfonyl fluoride (pro tease inhibitor) were added into the homogenization buffer. The components of homogenization was the same to the previous lysis buffer except that the buffer compound is HEPES instead of Tris as the amino group of tris(hydroxymethyl)aminomethane will interfere with the following OPT assay. The protein extract was directly used for activity assay.

Kinetic Assays—The catalytic efficiencies of HuGADL1 toward aspartate and cysteine sulfinic acid were determined by incubating 20 μg of enzyme in the presence of varying concentrations (0.1, 0.5, 1, 2, 5, 10, and 20 mM) of aspartate and cysteine sulfinic acid in 500 μl of 150 mM of phosphate buffer (pH 7.0) containing 0.40 μM of PLP. Fifty millimolars of aspartate and cysteine sulfinic acid were prepared as stock and adjusted to pH 7.0 using 1 M of phosphate buffer (pH 7.0). Each reaction was incubated for 10 min at 25 °C before analysis. The kinetic parameters and standard deviations were calculated based on the averages of triplicates. Lineweaver-Burk double reciprocal plots (1/V versus 1/S) were used to determine the Michaelis-Menten constant Kₘ and the maximum velocity Vₘₐₓ.

RNA Isolation—Total RNA was isolated using TRI Reagent® according to the manufacturer’s instruction (MRC, Cincinnati, OH). The extracted RNA was dissolved in diethylypyrocarbonate-treated water. Concentrations of total RNA were determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE).

RT-PCR—Total RNA (0.1 μg) was reverse transcribed into cDNA in a total volume of 20 μl using the ImProm-II reverse transcriptase (Promega) according to the manufacturer’s instruction. Ribosomal 18 S RNA was used as internal standard. To amplify the target gene, 5 ng of cDNA was mixed with 12.5 μl of 2 × PCR Master Mix (Promega) and 10 pmol of each corresponding primer in a total volume of 25 μl. The conditions for PCR were 32 cycles at 94 °C for 30 s, 55 °C for 1 min, and 72 °C for 30 s. The primers used for RT-PCR are shown in supplemental Table S1.

Western Blot Analysis—Frozen tissues (~0.5 g) and C2C12 cells were lysed in ice-cold radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease inhibitors (Roche Applied Science) and phosphatase inhibitors (0.5 mM Na₂VO₃, 5 mM sodium pyrophosphate, 50 mM NaF, 10 mM sodium β-glycerophosphate). The lysates were centrifuged at 12,000 × g for 15 min at 4 °C. The final supernatants were collected and stored at −80 °C. Protein concentrations of the supernatants were determined with a BCA protein assay kit (Thermo Scientific, Rockford, IL). For Western blot analyses, 40 μg of isolated total protein or 10 μg of purified CSADC protein was resolved by 10% SDS-PAGE and then transferred to a nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% nonfat dried milk in TBST buffer (20 mM Tris-HCl, 500 mM NaCl, and 0.05% Tween 20) and incubated with GADL1 antibody (Thermo Scientific) at 1:100 dilution in TBST with 5% BSA overnight at 4 °C. This antibody was detected using a horseradish peroxidase-conjugated goat IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and SuperSignal West Pico chemiluminescence substrate (Thermo Scientific). Following detection of GADL1 protein, the membrane was stripped with Restore Western blot Stripping Buffer (Thermo Scientific) and re-probed with the β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA).

RESULTS

Presence of GADL1 Gene in Species—Although not specified in the databases, human GADL1 is likely the first one named as GADL1, and the other GADL1 sequences likely have been based on the human sequence. To date, there have been several GADL1 genes in the databases. The deduced sequences from these genes are highly conserved. For example, GADL1 sequences from human, cattle, and mice share more than 90% sequence identity (supplemental Fig. S1). In human, GADL1 also shares considerable similarity with human GAD65 and GAD67, which likely explains why it has been named GAD-like protein. However, GADL1 shares noticeable better similarity (59% identity) with CSADC than with mammalian GAD sequences (50 and 51% identity) (supplemental Fig. S2).

UV-visible Spectrum of Recombinant HuGADL1—The concentrated protein solution showed a visible light yellow color. Spectral analysis of purified HuGADL1 revealed the presence of typical visible absorbance peaks with their λₘₐₓ at 340 and 430 nm, respectively (Fig. 2). These visible absorption peaks were due to the presence of PLP cofactor. The ratio of the 340-nm peak versus the 430-nm peak reflected the relative contents of PLP tautomers. Overall, the visible spectrum of HuGADL1 was quite similar to that of HuCSADC (9), except that HuGADL1 had a higher 340-nm/430-nm peak ratio (Fig. 2).

Substrate Specificity of HuGADL1—HuGADL1 was screened against all 20 proteogenic amino acids and also cysteine sulfinic acid and cysteic acid for decarboxylation activity. Among them, HuGADL1 showed decarboxylation activities with aspartate, cysteine sulfinic acid, and cysteic acid (Fig. 3, A–C) but dis-
played no activity with glutamate (Fig. 3D) and other amino acids. Fig. 3 (A–C) demonstrates that HuGADL1 has both ADC and CSADC activity. Under the applied assay conditions, the specific activity of HuGADL1 was 1.3 ± 0.2 μmol min⁻¹ mg⁻¹ to aspartate, 2.08 ± 0.3 μmol min⁻¹ mg⁻¹ to cysteine sulfenic acid, and 0.46 μmol min⁻¹ mg⁻¹ to cysteic acid, respectively. Based on its substrate specificity, HuGADL1 could be called a HuCSADC isozyme or named HuADC. When the enzyme was incubated with aspartate and cysteine sulfenic acid at the same time, its CSADC activity was not affected to any significant degree, but its ADC activity was considerably reduced (Fig. 3E), indicating that cysteine sulfenic acid competes much more effectively than aspartate in HuGADL1 binding. For example, in the presence of 10 mM of cysteine sulfenic acid and 5 mM of aspartate, the calculated CSADC activity and ADC activity were ~1.67 and 0.06 μmol min⁻¹ mg⁻¹ (Fig. 3E, left panel), respectively. When GADL1 was incubated with cysteine sulfenic acid and aspartate with each at 10 mM final concentration, its CSADC activity and ADC activity were ~1.41 and 0.12 μmol min⁻¹ mg⁻¹ (Fig. 3E, middle panel), respectively. When the enzyme was incubated with 5 mM of cysteine sulfenic acid and 10 mM of aspartate, the CSADC activity and ADC activity were ~1.29 and 0.22 μmol min⁻¹ mg⁻¹ (Fig. 3E, right panel), respectively. Fig. 3F shows the elution profile of hypotaurine, taurine, β-alanine, and GABA in our assay conditions.

**Kinetic Parameters of HuGADL1 to Aspartate and Cysteine Sulfenic Acid—HuGADL1 showed moderate substrate affinity to aspartate and cysteine sulfenic acid. Although the enzyme showed overall better affinity and catalytic efficiency to cysteine sulfenic acid than to aspartate (Table 1), the concentration of aspartate is generally much higher than that of cysteine sulfenic acid in many tissues. Therefore, the enzyme could be functional primarily as ADC or CSADC, depending on its locations.**

**Tissue Distribution of GADL1 mRNA—**Tissue distributions of GADL1 mRNA of mice and cattle were determined by RT-PCR using ribosomal 18 S RNA as an internal standard for cDNA normalization. In mice, GADL1 mRNA expression was detected at high levels only in skeletal muscles and kidneys (Fig. 4A). In cattle, GADL1 mRNA was detected in skeletal muscles and hearts, but transcript abundance was much greater in muscles than in hearts (Fig. 4B). GADL1 mRNA was not found in mouse brains (supplemental Fig. S3). The GADL1 mRNA was detected from C2C12 myoblasts but not from C2C12 myotubes.

**Western Blot Analysis—**The presence of GADL1 was investigated in mouse muscles, kidneys, C2C12 myoblasts, and C2C12 myotubes. Antibody against β-actin was used as an internal control. Purified recombinant mouse CSADC was used to test the specificity of the GADL1 antibody. The result showed that GADL1 is present in muscles, kidneys, C2C12 myoblasts, and C2C12 myotubes (Fig. 5, A and B). These results are comparable with the RT-PCR data, except that GADL1 transcript was not detected from C2C12 myotubes (supplemental Fig. S3). It is possible that GADL1 in C2C12 myotubes might be carried over from the myoblast stage of the muscle cells. It was also noted that the GADL1 antibody cross-reacted with mouse CSADC (Fig. 5C). Trace amounts of CSADC were detected from kidney samples but not from muscle samples (Fig. 5A).

**Activity Assay Using Protein Extracts—**The ADC and CSADC activities were investigated with fresh protein extracts from kidneys and muscles, respectively. When the supernatant of freshly prepared muscle protein extracts was mixed with cysteine sulfenic acid and incubated for 10 min, no apparent accumulation of hypotaurine was observed, but the relative amount of taurine (Fig. 6A) was much greater than that of the endogenous taurine present in the supernatant of muscle protein extracts (see Fig. 6B as a reference). When the freshly prepared muscle sample was mixed with aspartate for 10 min, no apparent accumulation of β-alanine was observed in the reaction mixture (Fig. 6B). Because only aspartate was incubated with the supernatant, the taurine peak corresponded to the relative base level of taurine in the supernatant of muscle protein extracts (Fig. 6B). Based on the apparent increase of taurine concentration in the reaction mixture with cysteine sulfenic acid as a substrate, it seemed that no hypotaurine was produced in the reaction mixture, but hypotaurine, once formed, was converted to taurine. When hypotaurine was directly mixed with muscle extract sample, hypotaurine was also converted to taurine (supplemental Fig. S4), suggesting that crude muscle extract contains factor(s) capable of oxidation of hypotaurine to taurine. Compared with the high concentration of endogenous taurine, no endogenous β-alanine peak was observed in the supernatant of muscle protein extracts. Also, no apparent decrease of β-alanine was observed when the compound was incubated with muscle extract sample (supplemental Fig. S5).

When the supernatant of freshly prepared kidney protein extracts was incubated with cysteine sulfenic acid as a substrate, accumulation of hypotaurine was observed in the reaction mixture (Fig. 6C). When the kidney sample was incubated with aspartate, no apparent accumulation of β-alanine was observed in the reaction mixture (Fig. 6D). It is worth noting that, when substrate was incubated with the supernatant of muscle protein extracts, the majority of product was found in the form of tau-
FIGURE 3. Substrate specificities of recombinant HuGADL1. Chromatograms A, B, and C show the accumulation of hypotaurine in a HuGADL1 and cysteine sulfinic acid reaction mixture, the accumulation of taurine in a HuGADL1 and cysteic acid reaction mixture, and the accumulation of β-alanine in a HuGADL1 and aspartate reaction mixture, respectively. Chromatogram D shows the absence of GABA in the HuGADL1 and glutamate reaction mixture. Chromatogram E shows a comparative study of the substrate preference of HuGADL1 under different concentrations of substrates. Chromatogram F illustrates the retention time of hypotaurine, taurine, β-alanine, and GABA standards under the same assay conditions. The reaction was initiated by the addition of purified HuGADL1 into each substrate preparation. An equal volume of 100% ethanol was added to each reaction mixture at 10 min after incubation at 25 °C, followed by the addition of two volumes of OPT agent. The mixture was incubated for 3 min. Determination of the products was based on the detection of OPT derivatives by reverse phase liquid chromatography with electrochemical detection. A C18 reverse phase column (4.6 mm × 100 mm, 5-μm spherical particle) was used for substrate and product separation. The mobile phase consisted of 50 mM phosphate buffer (pH 3.5) containing 25% acetonitrile with a flow rate of 0.5 ml/min. The working electrode was maintained at +0.75 V versus an Ag/AgCl reference electrode.
TABLE 1

| Enzyme      | Substrate          | $K_m$ [mM] | $V_{max}$ [umol/min/mg] | $k_{cat}$ [s$^{-1}$] | $k_{cat}/K_m$ [s$^{-1}$-mM$^{-1}$] |
|-------------|-------------------|------------|-------------------------|-----------------------|----------------------------------|
| HuGADL1     | Aspartate         | 2.72 ± 0.22 | 1.56 ± 0.12             | 1.3                   | 0.48                             |
|             | Cysteine sulfinic acid | 1.14 ± 0.14 | 2.31 ± 0.27             | 1.9                   | 1.67                             |

FIGURE 4. RT-PCR analysis of GADL1 in mice and cattle tissues. The tissue distribution of GADL1 mRNA was studied in mice (A) and cattle (B). Ribosomal 18 S RNA was used as an internal standard for both species.

FIGURE 5. Western blot analysis of GADL1 in tissues and cell culture. A, the presence of GADL1 in mouse kidneys and muscles. Notice that a lower band was detected in kidneys; this band corresponded to CSADC. B, the presence of GADL1 in mouse C2C12 myoblasts and myotubes. C, 10 μg of purified mouse CSADC was used to detect whether the GADL1 antibody had cross-reactivity. Antibody against β-actin was used as a control.

DISCUSSION

In this manuscript, we reported for the first time the biochemical activities of recombinant HuGADL1 and the distribution of GADL1 mRNA in mice and cattle. The recombinant HuGADL1, expressed in E. coli, has a UV-visible spectrum similar to that of other identified glutamate/cysteine sulfinic acid/aspartate 1-decarboxylases. HuGADL1 has different substrate usage than the name would imply. The enzyme catalyzes decarboxylation of $\alpha$-carboxyl group of cysteine sulfinic acid and aspartate but not glutamate. GADL1 mRNA showed tissue-specific expression in cattle and mice, with relatively high levels in the muscle of both species. High levels of GADL1 transcript were also detected in mouse kidneys. The presence of GADL1 in muscles and kidneys has been confirmed by Western blot analysis and activity assays with tissue samples. It is likely that GADL1 may contribute to in vivo taurine or/and β-alanine biosynthesis (supplemental Fig. S6). Consistent with our results in terms of GADL1 expression, online human microarray data indicated that GADL1 expression went up significantly under conditions of neuromuscular pain (ArrayExpress: E-GEOD-7307, Gene Expression Atlas). These online data have been derived from a number of independent DNA array studies. The linking of GADL1 with muscular pain conditions provides some basis to suggest that GADL1 plays a physiological role in muscles.

There are only a limited number of GADL1 genes in the Gene database with most of them from mammals. It was interesting to observe that although GADL1 from cattle and mouse is highly similar in primary sequence and both are transcribed primarily in skeletal muscles, the mouse gene is also transcribed a lot in kidney, and the cattle gene is transcribed a little in heart. In addition, GADL1 mRNA was detected in C2C12 myoblasts, a cell line corresponding to earlier stages of muscle ontogeny, but it disappeared in the next C2C12 myotube stage, indicating that GADL1 might be tightly regulated during myogenesis. The Western blot data indicated the presence of GADL1 in mouse muscles, kidneys, C2C12 myoblasts, and C2C12 myotubes, which is comparable with our RT-PCR data except for the C2C12 myotube result. Hypotaurine is the indispensable intermediate along the cysteine sulfinic acid to taurine pathway. Accumulation of taurine in the supernatant of muscle extracts and cysteine sulfinic acid reaction mixture determined the CSADC activity in muscles. Based on the Western blot analysis, however, typical CSADC was absent in muscles. Accordingly, the CSADC activity in muscles likely is primarily due to the presence of GADL1, whereas in kidney tissues, activity might well be a contribution by both typical CSADC and GADL1 as seen in Fig. 5A. It has been suggested that the hypotaurine-to-taurine reaction was enzyme-mediated, but there have been no reports or evidence showing the presence of such an enzyme. Conversion of hypotaurine to taurine in muscle samples suggested that a molecule/enzyme, capable of catalyzing the production of hypotaurine to taurine, is present in muscles (supplemental Fig. S4). No such activity was detected from brains and kidneys (data not shown). It is therefore worthwhile to work on the exact enzyme that was able to catalyze the conversion of hypotaurine to taurine.

HuGADL1 is active to cysteine sulfinic acid. Accordingly, it is reasonable to name it CSADC or CSADC isozyme. Although CSADC has generally been considered the primary enzyme for taurine synthesis, only a few mammalian CSADC enzymes have been experimentally characterized (16–18). Typical CSADC catalyzes cysteine sulfinic acid to hypotaurine that is the precursor of taurine and can be oxidized in vivo to taurine, but the enzyme has no activity to aspartate (9). Although past studies are not very consistent regarding the tissue distribution of mammalian CSADC, it is generally agreed it is expressed in both liver and brain (16, 19, 20). Although hearts and skeletal muscles have high concentrations of taurine, CSADC was not...
considered to be present in skeletal muscles and kidneys (16), and it was suggested that taurine was produced elsewhere and transported to these tissues (21, 22). In this study, the expression and biochemical activity of GADL1 in muscles suggested that muscle taurine might be produced in situ.

The other product of recombinant GADL1-catalyzed reactions is γ-alanine, a naturally occurring α-amino acid that is commonly found in many living species. γ-Alanine is a central component of pantothenate (vitamin B₅), the essential precursor of coenzyme A (23). γ-Alanine is also an important component of several dipeptides in animals, such as carnosine, carnosine, and N-γ-alanyldopamine. In humans (perhaps all other mammalian species as well), γ-alanine is necessary for carnosine synthesis. Carnosine, the dipeptide between l-histidine and γ-alanine, has long been considered the dominant buffering component in muscles (24). Increasing the intracellular carnosine levels has been exploited for improving the buffering capacity of skeletal muscles, thus enhancing exercise performance (14, 25). Carnosine is present at high concentrations in vertebrate skeletal muscles (24). In addition to muscles, carnosine is also found in brains and hearts and is therefore suspected to be more than a buffering reagent in physiology (26–30). Studies of carnosine have suggested that it has neuroprotective (31, 32), anti-inflammatory (33), antioxidative (34), and anti-aging activities (35, 36).

Living species seem to have evolved different biochemical processes to generate β-alanine, and some have more than one β-alanine producing pathway. It has been a general consensus that β-alanine is mainly derived from the degradation of uracil in plants, fungi, and vertebrates (37). In contrast, β-alanine is produced primarily through one-step decarboxylation of α-carboxyl group of aspartate by ADC in bacteria and insects, although the insect ADC and bacterial ADC share no sequence homology and are recruited independently by convergent evolution (38, 39). The bacterial ADC is a homotetramer with a covalently bound pyruvyl cofactor (40), whereas the insect ADC is a dimer with PLP as a cofactor (9).

The discovery of ADC activity of recombinant HaGADL1 is interesting and potentially quite important. Currently, except for insect ADC, no animal enzyme is known that is capable of catalyzing the decarboxylation of the α-carboxyl group of aspartate to β-alanine. Endogenous carnosine is synthesized by carnosine synthetase using histidine and β-alanine as substrates in muscles (41, 42). β-Alanine is the limiting compound in carnosine synthesis because its plasma concentration is much lower than that of histidine (24), and the enzyme has a lower affinity to β-alanine than to histidine (43, 44). All the currently known β-alanine-synthesizing enzymes have low expression levels in muscles, where the demand for β-alanine is great; accordingly, it is generally considered that the intramuscular β-alanine is transported from elsewhere to make carnosine (13). A study with chicken embryonic muscle cell culture indicated that a β-amino acid transporter is present in the cells (45); hence the sarcoplasmic β-alanine delivery is the rate-limiting factor for muscle carnosine synthesis. β-Alanine supplementation has been exploited to boost the blood β-alanine concentration, drive the carnosine synthesis in muscles, and improve muscle performance (46). Long term β-alanine intake has been shown to augment muscle carnosine concentrations (25, 47, 48), but such delivery is inefficient and somewhat problematic. Even with multiple high doses of 800 mg of β-alanine/day over 4 weeks, the mean increase of carnosine was only ~60% (24). Moreover, acute oral β-alanine intake (>800 mg) can cause paraesthesia, generally known as the feelings of "pins and needles" (49). Compared with the enzymatic β-alanine production and transportation pathways mentioned above, GADL1-mediated β-alanine production could be the simple and energy-efficient pathway.

ADC activity in muscle extracts remains to be established. Our recent data showed that cysteine could inactivate the insect ADC, and the two activities of the enzyme responded differently to cysteine inactivation, with its ADC activity being more potently inactivated (50). Cysteine sulfenic acid or/and hypotaurine can inhibit the ADC activity of GADL1 (Fig. 3E). Further analysis indicated that cysteine and taurine could severely inhibit the ADC activity of GADL1 as well (supplemental Fig. S7). It is possible that homogenization disrupted most organelles, which might expose GADL1 to endogenous inhibi-
tors, which may explain in part our inability to detect ADC activity in the extracted protein samples.

From an evolutionary perspective, GAD and CSADC appeared early in evolution, but so far GADL1 has only been found only in birds, reptiles, and mammals (Fig. 1). Although insect ADC possesses a similar substrate usage to GADL1 (9, 50), insect ADC-type enzymes have not been found in non-insect species (Fig. 1). GADL1 appeared late in species evolution. One might argue that GADL1 is still an evolving protein, its appearance may help those animals better adapt the much more complex terrestrial environment and whose better survival may somewhat depend on their muscle performance.

In summary, although the in vivo ADC activity of GADL1 is still in question, the distribution and biochemical activities of the recombinant HuGADL1 provide a basis to more intelligently explore its physiological function(s). The hypotaurine-generating activity of GADL1 was shown in muscles and kidneys; the up-regulation of GADL1 in muscles under disease conditions (reported by independent mRNA array analyses) indicates that the protein plays a physiological function(s) in muscles. Consequently, results of this study provide 1) useful information toward a more appropriate classification/annotation of GADL1 proteins, 2) a tangible basis in terms of directions for revealing its true physiological function(s), and 3) a stimulating momentum for studying these intriguing proteins.

REFERENCES

1. Bouché, N., Lacombe, B., and Fromm, H. (2003) GABA signaling. A conserved and ubiquitous mechanism. Trends Cell Biol. 13, 607–610
2. Bouché, N., Fait, A., Bouchez, D., Maller, S. G., and Fromm, H. (2003) Mitochondrial succinic-semialdehyde dehydrogenase of the y-amino- butyrylate shunt is required to restrict levels of reactive oxygen intermediates in plants. Proc. Natl. Acad. Sci. U.S.A. 100, 6843–6848
3. Chevrot, R., Rosen, R., Haudecoeur, E., Cirou, A., Shelp, B. J., Ron, E., and Faure, D. (2006) GABA controls the level of quoror-sensing signal in Agrobacterium tumefaciens. Proc. Natl. Acad. Sci. U.S.A. 103, 7460–7464
4. Fenalti, G., Law, R. H., Buckle, A. M., Langendorf, C., Tuck, K., Rosado, C. J., Faux, N. G., Mahmood, K., Hampe, C. S., Banga, J. P., Wilce, M., Schmittberger, J., Rossjohn, J., El-Kabbani, O., Pike, R. N., Smith, A. I., Mackay, I. R., Bowley, M. J., and Whistin, J. C. (2007) GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat. Struct. Mol. Biol. 14, 280–286
5. Capitani, G., De Biase, D., Aurizi, C., Gut, H., Bossa, F., and Grütter, M. G. (2003) Crystal structure and functional analysis of Escherichia coli glutamate decarboxylase. EMBO J. 22, 4027–4037
6. Battaglioni, G., Liu, H., and Martin, D. L. (2003) Kinetic differences between the isozymes of glutamate decarboxylase. Implications for the regulation of GABA synthesis. J. Neurochem. 86, 879–887
7. Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R. G., Kanbara, N., Kuzume, H., Sanbo, M., Yagi, T., and Obata, K. (1997) Elevated plasma and decreased brain y-amino butyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 94, 6496–6499
8. Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R., Li, F. Y., Kanbara, Kuzume, H., Sanbo, M., Yagi, T., and Obata, K. (1996) Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem. Biophys. Res. Commun. 229, 891–895
9. Liu, P., Ding, H., Christensen, B. M., and Li, J. (2012) Cysteine sulfenic acid decarboxylase activity of Aedes aegypti aspartate 1-decarboxylase. The structural basis of its substrate selectivity. Insect Biochem. Mol. Biol. 42, 396–403
10. Lohkamp, B., Voevodskaya, N., Lindqvist, Y., and Dobritsch, D. (2010) Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination. Biochim. Biophys. Acta 1804, 2198–2206
11. Hipkiss, A. R. (2009) Carnosine and its possible roles in nutrition and health. Adv. Food Nutr. Res. 57, 87–154
12. Derave, W., Everaert, I., Beeckman, S., and Baguet, A. (2010) Muscle carnosine metabolism and β-alanine supplementation in relation to exercise and training. Sports Med. 40, 247–263
13. Artioli, G. G., Gualano, B., Smith, A., Stout, J., and Lancha, A. H., Jr. (2010) Role of β-alanine supplementation on muscle carnosine and exercise performance. Med. Sci. Sports Exerc. 42, 1162–1173
14. Hill, C. A., Harris, R. C., Harris, B. D., Sale, C., Boobis, L. H., Kim, C. K., and Wise, J. A. (2007) Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Amino Acids 32, 223–233
15. Warskulat, U., Heller-Stibl, B., Oermann, E., Zilles, K., Haas, H., Lang, F., and Häussinger, D. (2007) Phenotype of the taurine transporter knockout mouse. Methods Enzymol. 426, 439–458
16. Park, E., Park, S. Y., Wang, C., Xu, J., LuFauci, G., and Schuller-Levis, G. (2002) Cloning of murine cysteine sulfenic acid decarboxylase and its mRNA expression in murine tissues. Biochim. Biophys. Acta 1574, 403–406
17. Wu, J. Y. (1982) Purification and characterization of cysteic acid and cysteine sulfenic acid decarboxylase and l-glutamate decarboxylase from bovine brain. Proc. Natl. Acad. Sci. U.S.A. 79, 4270–4274
18. Sköldberg, F., Rorsman, F., Perheentupa, J., Linard-OLsson, M., Husebye, E. S., Gustafsson, J., and Kane, Ö. (2004) Analysis of antibody reactivity against cysteine sulfenic acid decarboxylase, a pyridoxal phosphate–dependent enzyme, in endocrine autoimmune mice. J. Clin. Endocrinol. Metab. 89, 1636–1640
19. Ubu, T., Okada, A., and Nakamura, H. (2008) Production of hypertaurine from L-cysteinesulfinate by rat liver mitochondria. Amino Acids 35, 53–58
20. Wu, J. Y., Tang, X. W., Schloss, J. V., and Faiman, M. D. (1998) Regulation of taurine biosynthesis and its physiological significance in the brain. Adv. Exp. Med. Biol. 442, 339–345
21. Heller-Stibl, B., van Ruyen, C., Rascher, K., Hartwig, H. G., Huth, A., Seeliger, M. W., Warskulat, U., and Häussinger, D. (2002) Disruption of the taurine transporter gene (tau) leads to retinal degeneration in mice. FASEB J. 16, 231–233
22. Itô, T., Oishi, S., Takai, M., Kimura, Y., Uozumi, Y., Fujio, Y., Schaffer, S. W., and Azuma, J. (2010) Cardiac and skeletal muscle abnormality in taurine transporter–knockout mice. J. Biol. Chem. 285, 879–887
23. Webb, M. E., Smith, A. G., and Abell, C. (2004) Biosynthesis of pantothenate. Nat. Prod. Rep. 21, 695–721
24. Harris, R. C., Tallon, M. J., Dunnett, M., Boobis, L., Coakley, J., Kim, J. H., Fallowfield, J. L., Hill, C. A., Sale, C., and Wise, J. A. (2006) The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. Amino Acids 30, 279–289
25. Derave, W., Ozdemir, M. S., Harris, R. C., Pottier, A., Reyngoudt, H., Koppo, K., Wise, J. A., and Achten, E. (2007) β-Alanine supplementation augments muscle carnosine content and attenuates fatigue during repeated isokinetic contraction bouts in trained sprinters. J. Appl. Physiol. 103, 1736–1743
26. Zaloga, G. P., Roberts, P. R., and Nelson, T. E. (1996) Carnosine. A novel peptide regulator of intracellular calcium and contractility in cardiac muscle. New Horiz. 4, 26–35
27. Boldyreva, A. A. (1995) [Carnosine metabolism in excitable tissues. Biological significance]. Vestn. Ross Akad. Med. Nauk. 1995, 3–7
28. Jackson, M. C., and Lenney, J. F. (1996) The distribution of carnosine and related dipeptides in rat and human tissues. Inflamm. Res. 45, 132–135
29. Zaloga, G. P., Roberts, P. R., Black, K. W., Lin, Min, Zapata-Sudo, G., Sudo, R. T., and Nelson, T. E. (1997) Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. Am. J. Physiol. 272, H462–H468
30. Ajdin, A. F., Kucükgecerin, C., Ozdemirler-Erata, G., Gocek-Toker, N., and Uysal, M. (2010) The effect of carnosine treatment on prooxidant–antioxidant balance in liver, heart and brain tissues of male aged rats. Biogeront-
Role of GADL1 in Taurine Biosynthesis

1. Horning, M. S., Blakemore, L. J., and Trombley, P. Q. (2000) Endogenous mechanisms of neuroprotection. Role of zinc, copper, and carnosine. Brain Res. 852, 56–61.

2. Trombley, P. Q., Horning, M. S., and Blakemore, L. J. (2000) Interactions between carnosine and zinc and copper. Implications for neuromodulation and neuroprotection. Biochemistry 65, 807–816.

3. Hipkiss, A. R., Michaelis, J., and Syrris, P. (1995) Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett. 371, 81–85.

4. Boldyrev, A. A. (1993) Does carnosine possess direct antioxidant activity? Int. J. Biochem. 25, 1101–1107.

5. Chez, M. G., Buchanan, C. P., Aimonovitch, M. C., Becker, M., Schaefer, K., Black, C., and Komen, J. (2002) Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J. Child Neurol. 17, 833–837.

6. Hipkiss, A. R. (2009) On the enigma of carnosine's anti-ageing actions. Exp. Gerontol. 44, 237–242.

7. Brown, G. M., and Williamson, J. M. (1982) Biosynthesis of riboflavin, folic acid, thiamine, and pantothenic acid. Adv. Enzymol. Relat. Areas Mol. Biol. 53, 345–381.

8. Cronan, J. E., Jr. (1980) β-Alanine synthesis in Escherichia coli. J. Bacteriol. 141, 1291–1297.

9. Richardson, G., Ding, H., Rocheleau, T., Mayhew, G., Reddy, E., Han, Q., Christensen, B. M., and Li, J. (2010) An examination of aspartate decarboxylase and glutamate decarboxylase activity in mosquitoes. Mol. Biol. Rep. 37, 3199–3205.

10. Schmitzberger, F., Kilkenny, M. L., Lobley, C. M., Webb, M. E., Vinkovic, M., Matak-Vinkovic, D., Witty, M., Chirgadze, D. Y., Smith, A. G., Abell, C., and Blundell, T. L. (2003) Structural constraints on protein self-processing in L-aspartate-α-decarboxylase. EMBO J. 22, 6193–6204.

11. Drozak, J., Veiga-da-Cunha, M., Vertommen, D., Stroobant, V., and Van Schaftingen, E. (2010) Molecular identification of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1). J. Biol. Chem. 285, 9346–9356.

12. Bulygina, E. R., and Kramarenko, G. G. (1995) [Isolation of carnosine synthetase from animal and human muscles]. Vopr. Med. Khim. 41, 27–30.

13. Horinishi, H., Grillo, M., and Margolis, F. L. (1978) Purification and characterization of carnosine synthetase from mouse olfactory bulbs. J. Neurochem. 31, 909–919.

14. Ng, R. H., and Marshall, F. D. (1978) Regional and subcellular distribution of homocarnosine-carnosine synthetase in the central nervous system of rats. J. Neurochem. 30, 187–90.

15. Bakardjieva, A., and Bauer, K. (1994) Transport of β-alanine and biosynthesis of carnosine by skeletal muscle cells in primary culture. Eur. J. Biochem. 225, 617–623.

16. Stellingwerff, T., Decombaz, J., Harris, R. C., and Boesch, C. (2012) Optimizing human in vivo dosing and delivery of β-alanine supplements for muscle carnosine synthesis. Amino Acids 43, 57–65.

17. Kendrick, I. P., Harris, R. C., Kim, H. J., Kim, C. K., Dang, V. H., Lam, T. Q., Bui, T. T., Smith, M., and Wise, J. A. (2008) The effects of 10 weeks of resistance training combined with beta-alanine supplementation on whole body strength, force production, muscular endurance and body composition. Amino Acids 34, 547–554.

18. Kendrick, I. P., Kim, H. J., Harris, R. C., Kim, C. K., Dang, V. H., Lam, T. Q., Bui, T. T., and Wise, J. A. (2009) The effect of 4 weeks β-alanine supplementation and isokinetic training on carnosine concentrations in type I and II human skeletal muscle fibres. Eur. J. Appl. Physiol. 106, 131–138.

19. Décombaz, J., Beaumont, M., Vuichoud, J., Bouisset, F., and Stellingwerff, T. (2012) Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. Amino Acids 43, 67–76.

20. Liu, P., Torrens-Spence, M. P., Ding, H., Christensen, B. M., and Li, J. (2012) Mechanism of cysteine-dependent inactivation of aspartate/glutamate/cysteine sulfenic acid α-decarboxylases. Amino Acids DOI 10.1007/s00726–012-1342–7.